• NU7441 (KU-57788): Selective DNA-PK Inhibitor for DNA Repair

  2026-04-23

  NU7441 (KU-57788) is a potent, ATP-competitive DNA-PK inhibitor with high selectivity and nanomolar efficacy. It enables precise study of DNA repair and cell cycle regulation in oncology research. Its benchmarked specificity and robust in vitro/in vivo profiles make it a cornerstone for mechanistic and translational workflows.

• Balancing Self-Renewal and Differentiation in Human Intestin

  2026-04-22

  This article reviews a recent study that establishes an optimized human intestinal organoid system capable of balancing stem cell self-renewal with differentiation, without the need for artificial spatial gradients. The findings enable scalable, diverse organoid cultures and provide a foundation for advanced applications in disease modeling and drug testing.

• miR-18a Suppresses Ferroptosis via ALOXE3 Downregulation in

  2026-04-22

  This study uncovers a novel oncogenic axis in glioblastoma, demonstrating that miR-18a promotes tumor progression by directly targeting and suppressing ALOXE3, thereby reducing ferroptotic and anti-migratory activities. The mechanistic insights into lipid metabolism and ferroptosis open new avenues for therapeutic strategies targeting the miR-18a/ALOXE3 pathway in aggressive brain tumors.

• LY2603618: Chk1 Inhibitor Workflow Optimization in Cancer Re

  2026-04-21

  LY2603618 is redefining DNA damage response studies by providing selective, ATP-competitive inhibition of Chk1—enabling robust cell cycle arrest and enhanced chemotherapy sensitization. This article delivers practical, evidence-backed workflows and troubleshooting strategies for maximizing assay reproducibility and data impact using LY2603618 in cancer research.

• HOXC8 Suppresses Pyroptosis via Caspase-1 Regulation in NSCL

  2026-04-21

  This study uncovers a novel mechanism by which the transcription factor HOXC8 suppresses pyroptotic cell death in non-small cell lung carcinoma (NSCLC) through transcriptional repression of caspase-1, mediated by HDAC1/2 recruitment. These findings provide new insights into the interplay between epigenetic regulation and programmed cell death in lung tumorigenesis, with implications for targeted cancer research.

• Niclosamide in STAT3 Pathway Inhibition: Protocols & Best Pr

  2026-04-20

  Niclosamide (5-chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxybenzamide) delivers precise STAT3 inhibition for robust cancer research workflows. This article details actionable protocol parameters, troubleshooting strategies, and the latest insights from advanced in vitro assay development, empowering researchers to achieve reproducible and mechanistically clear results.

• MLKL-Induced Lysosomal Permeabilization Drives Necroptosis v

  2026-04-20

  This study demonstrates that polymerized MLKL translocates to lysosomal membranes, inducing their permeabilization and releasing cathepsin B, which is essential for necroptotic cell death. The work clarifies the mechanistic link between MLKL polymerization, lysosomal disruption, and cathepsin B–mediated necroptosis, informing both basic cell death research and therapeutic exploration.

• 5-(N,N-dimethyl)-Amiloride Hydrochloride in Endothelial Inju

  2026-04-19

  Unlock the full experimental potential of 5-(N,N-dimethyl)-Amiloride hydrochloride for precise Na+/H+ exchanger inhibition in endothelial and cardiac research. This article details actionable workflows, advanced troubleshooting, and translational guidance based on recent biomarker discoveries and robust literature.

• Inducing Embryonic Dormancy In Vitro via mTOR Inhibition Pro

  2026-04-18

  This study presents a detailed, noninvasive protocol to induce a diapause-like dormant state in mouse and human early embryonic cells using pharmacological mTOR inhibition. The approach provides a scalable and reversible system for studying dormancy mechanisms, advancing both developmental biology and assisted reproductive technology research.

• Cyclosporin A: Protocol Optimization in Immunosuppression Re

  2026-04-17

  Cyclosporin A is a cornerstone for immunosuppression, apoptosis, and viral entry inhibition studies. This article delivers workflow enhancements, troubleshooting tips, and evidence-driven parameterization to ensure robust, reproducible results with APExBIO’s Cyclosporin A across diverse experimental models.

• Ademetionine in Neurological Disorders: Methylation and CNS

  2026-04-16

  This review by Bottiglieri et al. examines the biochemical roles and clinical potential of Ademetionine (S-adenosylmethionine, SAMe) in treating neurological disorders. By analyzing the interplay between methylation pathways and CNS pathophysiology, the article highlights SAMe’s influence on neurotransmitter metabolism, its antidepressant activity, and its implications for dementia and other neuropsychiatric conditions.

• Bafilomycin A1: Precision V-ATPase Inhibitor for Cell Biolog

  2026-04-15

  Bafilomycin A1 is a selective, reversible V-ATPase inhibitor with nanomolar potency. It is widely used in lysosomal function research and intracellular pH regulation. APExBIO provides a rigorously validated reagent for advanced workflows.

• Erastin as a Ferroptosis Inducer: Protocols & Advanced Uses

  2026-04-14

  Erastin is a gold-standard ferroptosis inducer, enabling precise investigation of iron-dependent, non-apoptotic cell death in RAS/BRAF-mutant tumor models. This guide delivers detailed protocols, troubleshooting insights, and actionable takeaways from the latest research, streamlining oxidative stress assays and cancer biology applications.

• Mechanisms of DON-Induced Liver Injury: Mitophagy and Nrf2 P

  2026-04-13

  This study elucidates how deoxynivalenol (DON) causes liver injury by overactivating PINK1/Parkin-mediated mitophagy while suppressing the cytoprotective p62-Keap1-Nrf2 pathway. These findings enhance mechanistic understanding of DON hepatotoxicity and inform the design of targeted intervention strategies and experimental liver injury models.

• NMDA Agonism: Strategic Leverage for Excitotoxicity Models

  2026-04-13

  This article navigates the mechanistic, experimental, and translational landscape of NMDA (N-Methyl-D-aspartic acid) as a gold-standard tool in excitotoxicity and neurodegenerative disease research. It connects recent advances, including the modeling of ferroptosis in glaucoma, to protocol optimization and competitive considerations, offering actionable guidance for translational researchers seeking to build robust, reproducible workflows.

15448 records 1/1030 page Next 12345 下5页 Last page